Nura Bio
South San Francisco
About Nura Bio
Nura Bio is a clinical-stage biopharmaceutical company focused on developing neuroprotective therapies to treat neurological diseases. Nura Bio’s drug candidate, NB-4746, is designed to inhibit the SARM1 protein, which plays a significant role in axon degeneration. This drug has shown promise in preclinical studies for preventing nerve damage and is currently advancing toward phase 1b/2 clinical trials in 2025. The company has raised $140 million in financing to support this and other neuroprotective drug programs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $141.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Sep 2024)
- Website: nurabio.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical, Neuroscience, Wellness
Social Profiles
Canonical: https://fsome.com/organization/nura-bio-55652 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.